trial

Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement

NCTId NCT04323566

as of 2026-07-01

Add to landscape Monitor this Ask about this

at a glance

Phase 2 · Enrolling By Invitation

Enrollment 40 (estimated)

Sponsored by Uppsala University Hospital

Primary completion 2028-04-01

Synthesized from structured facts only — each point cited above.

Design & status

Phase

Phase 2

Status

Enrolling By Invitation

Enrollment

40 (estimated)

Study type

Interventional

Allocation

Randomized

Model

Crossover

Masking

Quadruple

Start

2022-05-01

Primary completion

2028-04-01

Eligibility

ALL · 18 Years · 55 Years

Interventions & indications

Drugs

Rituximab

Indications

Schizo Affective Disorder Unspecified Psychosis Schizophrenia, Paranoid Psychotic Disorders Obsessive-Compulsive Disorder Obsessive-Compulsive Behavior Schizophrenia Schizophrenia Brief Psychotic Disorder Other Psychoses Compulsive Behavior Obsessive-Compulsive Disorder

Investigators

Janet L Cunningham, MD PhDPrincipal Investigator

Sites

1 total

Uppsala, Sweden

Linked catalysts

Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Prob — primary completion2028-04-01

Facts & assertions

4 sourced

Enrollment

Phase

PHASE2

Primary Completion Date

2028-04-01

Status

ENROLLING_BY_INVITATION

relationships

The graph out of here

drug

Rituximab

drug

lead_sponsor

Uppsala University Hospital

company

collaborator

Uppsala University Hospital

company

indication

Schizo Affective Disorder

indication

Unspecified Psychosis

indication

Schizophrenia, Paranoid

indication

investigator

Janet L Cunningham, MD PhD

person